{
    "clinical_study": {
        "@rank": "11429", 
        "arm_group": {
            "arm_group_label": "RO5520985", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This multi-center, open-label study will evaluate the safety, pharmacokinetics,\n      pharmacodynamics and preliminary efficacy of RO5520985 in patients with locally advanced or\n      metastatic solid tumors. Cohorts of patients will receive escalating doses of RO5520985\n      intravenously every 2 weeks. Anticipated time on study treatment is until disease\n      progression or unacceptable toxicity occurs."
        }, 
        "brief_title": "A Study of RO5520985 in Patients With Locally Advanced or Metastatic Solid Tumors", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Patients with histologically or cytologically confirmed locally advanced or\n             metastatic, non-resectable solid tumors whose disease has progressed despite standard\n             therapy or for whom no standard therapy exists\n\n          -  Measurable disease as determined by RECIST 1.1\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n\n          -  Adequate hematological function\n\n          -  Adequate liver function\n\n          -  Adequate renal function\n\n          -  Adequate coagulation\n\n          -  Adequate cardiovascular function\n\n          -  Recovery from all reversible adverse events of previous anti-cancer therapies to\n             baseline or CTCAE G 1, except for alopecia (any grade) and < or = G 2 sensory\n             peripheral neuropathy\n\n        Exclusion Criteria:\n\n          -  Patients with primary CNS tumors or CNS tumor involvement. Patients with metastatic\n             CNS tumors may participate in this trial under conditions defined by protocol\n\n          -  Patients with squamous non-small cell lung cancer histology\n\n          -  Prior treatment with anti-angiogenic agents targeting VEGF/Ang-1/Ang-2/PIGF and its\n             receptors within 6 months prior to study drug administration\n\n          -  Prior systemic anti-cancer therapy within the following timeframes: a) cyclical\n             chemotherapy within a period of time that is shorter than the cycle length for the\n             treatment used prior to study drug administration; b) biologic therapy or continuous\n             or intermittent treatment with small molecule therapeutics (targeted therapies)\n             within 4 weeks or < or = 5 half-lives of the drug concerned (whichever is shorter)\n             prior to study drug administration\n\n          -  Treatment with any other investigational agents within less than the cycle length\n             used for that treatment or within 4 weeks (whichever is shorter) prior to study drug\n             administration\n\n          -  Major surgery within 4 weeks prior to study drug administration\n\n          -  Significant cardiovascular/cerebrovascular disease within 6 months prior to study\n             drug administration\n\n          -  Known HIV infection or known active hepatitis B or hepatitis C virus infection\n\n          -  Pregnant or nursing women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "102", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01688206", 
            "org_study_id": "BP28179", 
            "secondary_id": "2011-005877-22"
        }, 
        "intervention": {
            "arm_group_label": "RO5520985", 
            "description": "Phase 1, First in Human Study of RO5520985", 
            "intervention_name": "RO5520985", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33076"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France", 
                        "zip": "14076"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69373"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75231"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94805"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08003"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28050"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46010"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "France", 
                "Spain"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Multi-center, Dose Escalation Phase I Study of Single Agent RO5520985, Administered as an Intravenous Infusion in Patients With Locally Advanced or Metastatic Solid Tumors.", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: BP28179 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Ministry of Health"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Dose-limiting toxicities/maximum tolerated dose", 
            "safety_issue": "Yes", 
            "time_frame": "approximately 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01688206"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 168 hours post-dose, Cycles 1-4"
            }, 
            {
                "measure": "Efficacy: Tumor response according to RECIST 1.1 criteria", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Pharmacodynamic effects assessed by bio-imaging/paired tumor biopsies", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}